Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading down 21 points (-0.1%) at 18,193 as of Friday, Feb. 27, 2015, 12:05 PM ET. The NYSE advances/declines ratio sits at 1,682 issues advancing vs. 1,233 declining with 204 unchanged.

The Health Care sector currently sits down 0.2% versus the S&P 500, which is unchanged. On the negative front, top decliners within the sector include

Allscripts Healthcare Solutions

(

MDRX

), down 8.2%,

Herbalife

(

HLF

), down 7.0%,

Alnylam Pharmaceuticals

(

ALNY

), down 2.6%,

Medivation

(

MDVN

), down 2.6% and

Envision Healthcare Holdings

(

EVHC

), down 2.5%. Top gainers within the sector include

Bio-Rad Laboratories

(

BIO

), up 4.8%,

Fresenius Medical Care AG & Co. KGaA

(

FMS

), up 2.8%,

Mylan

(

MYL

), up 1.8% and

Humana

(

HUM

), up 0.5%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3.

Becton Dickinson

(

BDX

) is one of the companies pushing the Health Care sector lower today. As of noon trading, Becton Dickinson is down $1.68 (-1.1%) to $146.86 on light volume. Thus far, 432,082 shares of Becton Dickinson exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $146.84-$148.90 after having opened the day at $148.90 as compared to the previous trading day's close of $148.54.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. Becton Dickinson has a market cap of $28.6 billion and is part of the health services industry. Shares are up 6.7% year-to-date as of the close of trading on Thursday. Currently there are 11 analysts that rate Becton Dickinson a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Becton Dickinson

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Becton Dickinson Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading,

Medtronic

(

MDT

) is down $0.60 (-0.8%) to $78.20 on light volume. Thus far, 965,223 shares of Medtronic exchanged hands as compared to its average daily volume of 8.8 million shares. The stock has ranged in price between $78.17-$78.76 after having opened the day at $78.61 as compared to the previous trading day's close of $78.81.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Medtronic plc, a healthcare solutions company, provides medical technologies, services, and solutions worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group. Medtronic has a market cap of $77.4 billion and is part of the health services industry. Shares are up 9.2% year-to-date as of the close of trading on Thursday. Currently there are 14 analysts that rate Medtronic a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates

Medtronic

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, solid stock price performance, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Medtronic Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading,

Gilead

(

GILD

) is down $0.75 (-0.7%) to $103.44 on light volume. Thus far, 2.6 million shares of Gilead exchanged hands as compared to its average daily volume of 16.9 million shares. The stock has ranged in price between $103.10-$104.34 after having opened the day at $104.28 as compared to the previous trading day's close of $104.19.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $157.5 billion and is part of the drugs industry. Shares are up 10.5% year-to-date as of the close of trading on Thursday. Currently there are 13 analysts that rate Gilead a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Gilead

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Gilead Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

null